CL2014000204A1 - Construcción de unión de antígeno que comprende dos anticuerpos de dominio (dabs) separados por una región fc; metodo para construir dicha construcción. - Google Patents

Construcción de unión de antígeno que comprende dos anticuerpos de dominio (dabs) separados por una región fc; metodo para construir dicha construcción.

Info

Publication number: CL2014000204A1
Authority: CL; Chile
Prior art keywords: dabs; build; construction; separated; region
Prior art date: 2011-07-27

Application number

CL2014000204A

Other languages

English (en)

Inventor

Alan Peter Lewis

Claire Ashman

Ian Richard Catchpole

Thomas Zoe Hughes

Michael Steward

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-27

Filing date

2014-01-27

Publication date

2014-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46579044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000204(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-01-27 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2014-07-25 Publication of CL2014000204A1 publication Critical patent/CL2014000204A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CL2014000204A 2011-07-27 2014-01-27 Construcción de unión de antígeno que comprende dos anticuerpos de dominio (dabs) separados por una región fc; metodo para construir dicha construcción. CL2014000204A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161512138P	2011-07-27	2011-07-27

Publications (1)

Publication Number	Publication Date
CL2014000204A1 true CL2014000204A1 (es)	2014-07-25

Family

ID=46579044

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000204A CL2014000204A1 (es)	2011-07-27	2014-01-27	Construcción de unión de antígeno que comprende dos anticuerpos de dominio (dabs) separados por una región fc; metodo para construir dicha construcción.

Country Status (19)

Country	Link
US (2)	US9499612B2 (es)
EP (1)	EP2736925A2 (es)
JP (1)	JP5987057B2 (es)
KR (1)	KR101632620B1 (es)
CN (1)	CN103842380A (es)
AU (1)	AU2012288846B2 (es)
BR (1)	BR112014001855A2 (es)
CA (1)	CA2842099A1 (es)
CL (1)	CL2014000204A1 (es)
CO (1)	CO7020847A2 (es)
CR (1)	CR20140047A (es)
DO (1)	DOP2014000017A (es)
EA (1)	EA028886B1 (es)
HK (1)	HK1198446A1 (es)
MA (1)	MA35352B1 (es)
MX (1)	MX2014001019A (es)
PE (1)	PE20141659A1 (es)
PH (1)	PH12014500220A1 (es)
WO (1)	WO2013014208A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
MX2013005847A (es) *	2010-11-24	2013-12-12	Glaxo Group Ltd	Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
CA3141978A1 (en)	2011-06-23	2012-12-27	Ablynx Nv	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2015200905A2 (en)	2014-06-28	2015-12-30	Oligasis, Llc	Dual pdgf/vegf antagonists
JP6929771B2 (ja)	2014-11-10	2021-09-01	ジェネンテック，インコーポレイテッド	抗インターロイキン−３３抗体及びその使用
CN107428828A (zh)	2015-03-11	2017-12-01	葛兰素史密斯克莱知识产权发展有限公司	Tslp结合蛋白
IL290457B2 (en)	2015-12-30	2025-02-01	Kodiak Sciences Inc	Antibodies and their conjugates
KR20180127344A (ko) *	2016-03-16	2018-11-28	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	단백질 A 결합 펩타이드, 항-EphA2 항체 및 이의 사용 방법
RU2018138122A (ru)	2016-04-05	2020-05-12	Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Новая терапия
US20200040084A1 (en) *	2017-01-06	2020-02-06	Momenta Pharmaceuticals, Inc.	Compositions and methods related to engineered fc-antigen binding domain constructs
CN109021103B (zh) *	2017-06-12	2022-08-23	上海睿智化学研究有限公司	抗人血管内皮生长因子的抗体及其制备方法和应用
CA3092588A1 (en)	2018-03-02	2019-09-06	Kodiak Sciences Inc.	Il-6 antibodies and fusion constructs and conjugates thereof
EP3586860A1 (en) *	2018-06-22	2020-01-01	Universität Ulm	Complement inhibitors and uses thereof
CA3157509A1 (en)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Methods of treating an eye disorder
EP4118114A1 (en)	2020-03-13	2023-01-18	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
EP4294839A1 (en) *	2021-02-19	2023-12-27	DotBio Pte. Ltd.	Vegfa-binding molecules
WO2023014892A1 (en) *	2021-08-04	2023-02-09	Alpine Biotherapeutics Corporation	Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders
CN118043350A (zh) *	2021-08-13	2024-05-14	信达生物制药(苏州)有限公司	抗vegf a和vegf c双特异性抗体及其用途
CN116064396A (zh) *	2021-10-29	2023-05-05	拜澳泰克(沈阳)生物医学集团有限公司	表达TNF-a拮抗蛋白的间充质干细胞在治疗类风湿性关节炎中的应用
WO2024029876A1 (ko) *	2022-08-02	2024-02-08	주식회사 파노로스바이오사이언스	변형된 융합 단백질 및 이의 용도
WO2024055995A1 (zh) *	2022-09-14	2024-03-21	寻济生物科技（北京）有限公司	一种抗vegfa融合蛋白及其制备方法和应用
CN120025456B (zh) *	2024-03-13	2025-11-07	寻济生物科技（北京）有限公司	一种抗vegfa融合构建体及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4666884A (en)	1984-04-10	1987-05-19	New England Deaconess Hospital	Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4873316A (en)	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE69127749T2 (de)	1990-03-20	1998-04-16	The Trustees Of Columbia University In The City Of New York, New York, N.Y.	Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
PT1024191E (pt)	1991-12-02	2008-12-22	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
AU4116793A (en)	1992-04-24	1993-11-29	Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5747035A (en)	1995-04-14	1998-05-05	Genentech, Inc.	Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5702892A (en)	1995-05-09	1997-12-30	The United States Of America As Represented By The Department Of Health And Human Services	Phage-display of immunoglobulin heavy chain libraries
WO1997043316A1 (en)	1996-05-10	1997-11-20	Beth Israel Deaconess Medical Center, Inc.	Physiologically active molecules with extended half-lives and methods of using same
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
BR9908226A (pt)	1998-02-25	2000-10-24	Lexigen Pharm Corp	Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
ES2299244T3 (es)	1998-05-13	2008-05-16	Domantis Limited	Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
JP2002522063A (ja)	1998-08-17	2002-07-23	アブジェニックスインコーポレイテッド	増加した血清半減期を有する改変された分子の生成
IL127127A0 (en) *	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
HUP0104865A3 (en)	1999-01-15	2004-07-28	Genentech Inc	Polypeptide variants with altered effector function
EP2275540B1 (en)	1999-04-09	2016-03-23	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
CA2388245C (en)	1999-10-19	2012-01-10	Kyowa Kirin Co., Ltd.	The use of serum-free adapted rat cells for producing heterologous polypeptides
WO2001057065A2 (en)	2000-02-03	2001-08-09	Domantis Limited	Combinatorial protein domains
US6374470B1 (en)	2000-10-06	2002-04-23	Milliken & Company	Face plate for spun-like textured yarn
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1355919B1 (en)	2000-12-12	2010-11-24	MedImmune, LLC	Molecules with extended half-lives, compositions and uses thereof
US20060073141A1 (en)	2001-06-28	2006-04-06	Domantis Limited	Compositions and methods for treating inflammatory disorders
EP1423510A4 (en)	2001-08-03	2005-06-01	Glycart Biotechnology Ag	ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
US7696320B2 (en) *	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN101039959A (zh) *	2004-06-30	2007-09-19	杜门蒂斯有限公司	用于治疗炎性疾病的组合物和方法
AU2005269759A1 (en)	2004-07-21	2006-02-09	Glycofi, Inc.	Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7563443B2 (en) *	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
CN101061140B (zh) *	2004-09-17	2015-07-01	多曼蒂斯有限公司	单价结合cd40l的组合物和应用方法
US7923538B2 (en)	2005-07-22	2011-04-12	Kyowa Hakko Kirin Co., Ltd	Recombinant antibody composition
KR101318611B1 (ko)	2005-07-22	2013-11-13	교와 핫꼬 기린 가부시키가이샤	유전자 재조합 항체 조성물
MX2009012343A (es) *	2007-05-14	2010-02-10	Biogen Idec Inc	Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
CA2688434A1 (en) *	2007-06-06	2008-12-11	Domantis Limited	Polypeptides, antibody variable domains and antagonists
GB0724331D0 (en) *	2007-12-13	2008-01-23	Domantis Ltd	Compositions for pulmonary delivery
TW200944231A (en)	2007-11-30	2009-11-01	Glaxo Group Ltd	Antigen-binding constructs
EP2220115A2 (en) *	2007-12-13	2010-08-25	Glaxo Group Limited	Polypeptides, antibody variable domains & antagonists
EP3663318A1 (en) *	2008-01-07	2020-06-10	Amgen Inc.	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CA2753287A1 (en) *	2009-02-24	2010-09-02	Glaxo Group Limited	Antigen-binding constructs
EA201190273A1 (ru) *	2009-05-28	2012-12-28	Глаксо Груп Лимитед	Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз
US8703132B2 (en) *	2009-06-18	2014-04-22	Hoffmann-La Roche, Inc.	Bispecific, tetravalent antigen binding proteins
EP2504360B1 (en) *	2009-11-23	2018-08-15	Amgen Inc.	Monomeric antibody fc
MX2013005847A (es) *	2010-11-24	2013-12-12	Glaxo Group Ltd	Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
JP2014505698A (ja) *	2011-02-02	2014-03-06	グラクソグループリミテッド	新規抗原結合タンパク質

2012
- 2012-07-25 PH PH1/2014/500220A patent/PH12014500220A1/en unknown
- 2012-07-25 MX MX2014001019A patent/MX2014001019A/es unknown
- 2012-07-25 EA EA201391812A patent/EA028886B1/ru not_active IP Right Cessation
- 2012-07-25 HK HK14111941.1A patent/HK1198446A1/xx unknown
- 2012-07-25 BR BR112014001855A patent/BR112014001855A2/pt not_active IP Right Cessation
- 2012-07-25 AU AU2012288846A patent/AU2012288846B2/en not_active Ceased
- 2012-07-25 US US14/235,330 patent/US9499612B2/en not_active Expired - Fee Related
- 2012-07-25 JP JP2014522089A patent/JP5987057B2/ja not_active Expired - Fee Related
- 2012-07-25 WO PCT/EP2012/064632 patent/WO2013014208A2/en not_active Ceased
- 2012-07-25 KR KR1020147005082A patent/KR101632620B1/ko not_active Expired - Fee Related
- 2012-07-25 PE PE2014000126A patent/PE20141659A1/es not_active Application Discontinuation
- 2012-07-25 CA CA2842099A patent/CA2842099A1/en not_active Abandoned
- 2012-07-25 EP EP12738476.6A patent/EP2736925A2/en not_active Ceased
- 2012-07-25 CN CN201280047197.3A patent/CN103842380A/zh active Pending
2014
- 2014-01-27 DO DO2014000017A patent/DOP2014000017A/es unknown
- 2014-01-27 CL CL2014000204A patent/CL2014000204A1/es unknown
- 2014-01-28 CR CR20140047A patent/CR20140047A/es unknown
- 2014-01-29 CO CO14018316A patent/CO7020847A2/es unknown
- 2014-02-18 MA MA36759A patent/MA35352B1/fr unknown
2016
- 2016-10-14 US US15/294,058 patent/US20170029494A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PH12014500220A1 (en)	2019-03-22
JP5987057B2 (ja)	2016-09-06
US20140205604A1 (en)	2014-07-24
PE20141659A1 (es)	2014-11-21
CN103842380A (zh)	2014-06-04
AU2012288846A1 (en)	2014-02-06
MX2014001019A (es)	2014-05-13
MA35352B1 (fr)	2014-08-01
CO7020847A2 (es)	2014-08-11
JP2014523746A (ja)	2014-09-18
EA028886B1 (ru)	2018-01-31
KR101632620B1 (ko)	2016-06-23
BR112014001855A2 (pt)	2017-02-21
AU2012288846B2 (en)	2016-05-19
EP2736925A2 (en)	2014-06-04
CR20140047A (es)	2014-03-24
KR20140041908A (ko)	2014-04-04
WO2013014208A2 (en)	2013-01-31
WO2013014208A3 (en)	2013-05-10
US20170029494A1 (en)	2017-02-02
US9499612B2 (en)	2016-11-22
HK1198446A1 (en)	2015-04-24
DOP2014000017A (es)	2014-04-30
EA201391812A1 (ru)	2014-06-30
CA2842099A1 (en)	2013-01-31

Publication	Publication Date	Title
NO2023024I1 (no)	2023-05-30	Spesolimab, an ant-IL-36R antibody
HUE036663T2 (hu)	2018-07-30	Készítmény anti-alfa4béta7 antitesthez
HUE036664T2 (hu)	2018-07-30	Készítmény anti-alfa4béta7 antitesthez
HRP20181690T1 (hr)	2018-12-28	Varijante protutijela fc
SMT201800144T1 (it)	2018-05-02	Anticorpi anti-cd40, usi e metodi
CO6811812A2 (es)	2013-12-16	Anticuerpo anti-b7-h3
HUE056808T2 (hu)	2022-04-28	TGF-bétára specifikus antitestek
PT4459282T (pt)	2025-12-24	Anticorpo monoclonal contra interleucina-31
DK3275892T3 (da)	2020-04-06	Præfusions-rsv-f-antigener
CL2014002904A1 (es)	2015-02-06	Una composición geopolimérica de aluminosilicato; metodo de preparacion.
BR112014011900A2 (pt)	2017-05-16	um método de purificação de anticorpo
CR20140127A (es)	2014-08-20	Anticuerpo anti-abtcr
PL2686347T3 (pl)	2018-10-31	Przeciwciała przeciwko CD70
EP2813568C0 (en)	2025-04-23	MODIFIED FC REGION OF AN ANTIBODY
BR112014013034A2 (pt)	2017-12-19	método para produzir um anticorpo
CO7020862A2 (es)	2014-08-11	Proteinas de unión al antígeno cd27l
EP2679681A4 (en)	2015-01-28	FC RIIB SPECIFIC FC ANTIBODIES
CO6801637A2 (es)	2013-11-29	Formulaciones de anticuerpos
CL2014001640A1 (es)	2014-12-05	Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
BR112014001546A2 (pt)	2017-03-21	dispositivo para evaporar substâncias voláteis.
EP2788760A4 (en)	2015-07-15	RECOMBINANT DESAMIDED GLIADINE ANTIGEN
EA201301090A1 (ru)	2014-05-30	Антидоты антикоагулянтов
LT2742068T (lt)	2019-07-10	Nauji antikūnai prieš fosforilcholiną
CO6841994A2 (es)	2014-01-20	Anticuerpos
CL2013000688A1 (es)	2014-02-28	Procedimiento para obtener una composicion de igg a partir de una composicion de igg parcialmente purificada.